The price of your health: is our healthcare in danger?

Will every patient need a global medical file? Can an extra 250 million euro be made available for prevention? And when will there be a radical overhaul of hospital financing? These are just a few of the pressing questions that will be addressed during the book launch for “De prijs van uw gezondheid” (“The price of your health”) by Lieven Annemans at the Brussels campus of Vlerick Business School on 26 February. Afterwards, there will be a debate featuring prominent figures from the health sector.

UPDATE: Watch the pictures of this book launch event.

The event will start with a welcome from prof. dr. Leo Neels, Chairman of the Advisory Board of the Vlerick Healthcare Management Centre. “The health sector is the biggest employer in the country, accounting for 1 in 9 jobs. It is an important economic sector, with major pharmaceutical companies, and a very important scientific sector, since Belgian biomedical researchers are among the very best in the world. These elements underpinned the creation of the Vlerick Healthcare Management Centre”, explains Leo Neels.

“We will focus on management and financing of the hospital sector, business model innovation for life science companies and growth models for biotech and medtech companies. Finally, policy and regulation of clinical studies is also on our agenda, because Belgium is a leading European country in this in this area. After all, these are the strong points of the Belgian health sector, and policy must develop and maintain the right conditions for them”, adds prof. dr. Walter Van Dyck, who will run the Vlerick Healthcare Management Centre and develop the academic foundation and scientific research.

The book identifies the burning issues surrounding Belgian healthcare, but also serves as a guidebook for a rapid recovery. Our fantastic system runs the risk of being completely derailed, losing its affordability and solidarity. On one hand, resources are being wasted as a result of an excessive number of examinations and overtreatment. Where savings are being made, on the other hand, this often happens at the expense of the quality of the care. Furthermore, we are spending too little on effective prevention. The price we all pay for this is a high one. Expensive care, poorer quality and preventable health problems have become the order of the day. However, in his book, Lieven Annemans also proposes a rescue plan that draws on the system’s current strengths.

ABOUT LIEVEN ANNEMANS

Lieven Annemans is a professor of Health Economics at UGent and the VUB. He served as Chairman of the Flemish Health Council (Vlaamse Gezondheidsraad) for 8 years and is honorary chairman of the International Society for Pharmacoeconomics and Outcomes Research. He was recently invited to hold the Belgian Francqui Chair and is in great demand as a speaker in numerous media.

PRACTICAL INFO

  • EAN:  9789401412391
  • Date of publication: 11/02/2014
  • Format: Paperback
  • Number of pages: 168
  • Publisher: LannooCampus

Register or obtain more info from LannooCampus

Related news

  1. Is competition in healthcare the answer to austerity?

    Date: 18/11/2016
    Category: Research News
    On Thursday 27 October, the annual Vlerick Healthcare Conference took place at our Brussels campus, where the most notable contemporary and future problems of the healthcare sector were discussed.
  2. Your money or your life: a critical note

    Date: 29/09/2016
    Category: Opinions
    In this era of healthcare budget constraints there is worldwide outrage at the high prices of medicines. And doctors are quite rightly concerned about the question of whether all their patients will continue to have access to lifesaving medicines at affordable prices. However, according to professor Walter Van Dyck the solution does not lie in scrapping the patent system, nor demanding transparency regarding the costs incurred by the biopharmaceutical industry for the new medicines that they want to bring onto the market. The only solution to this issue lies in a conditional dialogue between the community and the innovative biopharmaceutical industry.
All articles